PRODUCT INFORMATION

BIIB129

Item No. 43712

CAS Registry No.:	2770960-52-4
Formal Name:	N-methyl-N-[cis-3-methyl-3-[[6-(1-methyl-1Hpyrazol-4-yl) pyrazolo[1,5-a]pyrazin-4-yl]oxy] cyclobutyl]-2-propenamide
MF:	$C_{19}H_{22}N_6O_2$
FW:	366.4
Purity:	≥98%
Supplied as:	A solid
Storage:	-20°C
Stability:	≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

BIIB129 is supplied as a solid. A stock solution may be made by dissolving the BIIB129 in the solvent of choice, which should be purged with an inert gas. BIIB129 is soluble (≥10 mg/ml) in DMSO. BIIB129 is sparingly soluble (1-10 mg/ml) in ethanol.

Description

BIIB129 is a covalent inhibitor of Bruton's tyrosine kinase (BTK).[1] It is selective for BTK over a panel of 403 additional kinases at 1 µM. BIIB129 inhibits CD69 activation in isolated human whole blood (IC_{50} = 7.9 nM). *In vivo*, BIIB129 inhibits anti-myelin oligodendrocyte glycoprotein (MOG) antibody-induced microglia activation in mice (ED_{50} = 1.5 mg/kg).

Reference

1. Himmelbauer, M.K., Bajrami, B., Basile, R., *et al*. Discovery and preclinical characterization of BIIB129, a covalent, selective, and brain-penetrant BTK inhibitor for the treatment of multiple sclerosis. *J. Med. Chem.* **67(10)**, 8122-8140 (2024).

CAYMAN CHEMICAL
1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA
PHONE: [800] 364-9897
[734] 971-3335
FAX: [734] 971-3640
CUSTSERV@CAYMANCHEM.COM
WWW.**CAYMANCHEM**.COM